His primary scientific interests are in Genetic enhancement, Viral vector, Molecular biology, Stem cell and Haematopoiesis. The various areas that Donald B. Kohn examines in his Genetic enhancement study include Virology, Retrovirus, Immunology, Immune system and Cytotoxic T cell. His Immunology study combines topics in areas such as Severe combined immunodeficiency, Adenosine deaminase deficiency and Adenosine deaminase.
His work deals with themes such as Gene expression, Reporter gene, Genetic transfer, Long terminal repeat and Transduction, which intersect with Molecular biology. His Stem cell study integrates concerns from other disciplines, such as Cas9 and Bone marrow. His Bone marrow study incorporates themes from Transplantation and Cell biology.
Donald B. Kohn focuses on Genetic enhancement, Immunology, Stem cell, Haematopoiesis and Viral vector. His study explores the link between Genetic enhancement and topics such as Virology that cross with problems in Vector. His Immunology research is multidisciplinary, incorporating elements of Hematopoietic stem cell transplantation, Severe combined immunodeficiency and Adenosine deaminase.
The Stem cell study combines topics in areas such as Genome editing and Cancer research. The concepts of his Haematopoiesis study are interwoven with issues in Progenitor cell, CD34 and Stromal cell. His Viral vector research integrates issues from Genetic transfer, Molecular biology, Vesicular stomatitis virus, Transduction and Gene delivery.
The scientist’s investigation covers issues in Genetic enhancement, Stem cell, Haematopoiesis, Immunology and Viral vector. His study in Genetic enhancement is interdisciplinary in nature, drawing from both Hematopoietic stem cell transplantation, Hematopoietic stem cell, Severe combined immunodeficiency and Bone marrow. The study incorporates disciplines such as Genome editing, Cancer research, Gene expression and Virology in addition to Stem cell.
Donald B. Kohn has researched Haematopoiesis in several fields, including Progenitor cell, CD34 and Ex vivo. His work in Immunology covers topics such as Transplantation which are related to areas like Oncology. He has included themes like Vector, Transgene and Gene delivery in his Viral vector study.
His primary areas of study are Genetic enhancement, Stem cell, Haematopoiesis, Immunology and Hematopoietic stem cell transplantation. Donald B. Kohn interconnects Hematopoietic stem cell, Clinical trial, Viral vector and Enzyme replacement therapy in the investigation of issues within Genetic enhancement. Within one scientific family, Donald B. Kohn focuses on topics pertaining to Genome editing under Stem cell, and may sometimes address concerns connected to Bioinformatics, Cas9 and Disease.
His Haematopoiesis study combines topics from a wide range of disciplines, such as Cancer research, Progenitor cell, CD8, CD34 and Bone marrow. His work on T cell as part of his general Immunology study is frequently connected to Leukocyte adhesion deficiency, thereby bridging the divide between different branches of science. His Hematopoietic stem cell transplantation research is multidisciplinary, relying on both Severe combined immunodeficiency, Oncology and Adenosine deaminase.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo
Nathalia Holt;Jianbin Wang;Kenneth Kim;Geoffrey Friedman.
Nature Biotechnology (2010)
Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.
Kohn Db;Weinberg Ki;Nolta Ja;Heiss Ln.
Nature Medicine (1995)
Gene therapy comes of age.
Cynthia E. Dunbar;Katherine A. High;J. Keith Joung;Donald B. Kohn.
Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo.
Pia-Maria Challita;Donald B. Kohn.
Proceedings of the National Academy of Sciences of the United States of America (1994)
Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009
Sung Yun Pai;Brent R. Logan;Linda M. Griffith;Rebecca H. Buckley.
The New England Journal of Medicine (2014)
Stable transduction of quiescent CD34+CD38− human hematopoietic cells by HIV-1-based lentiviral vectors
Scott S. Case;Mary A. Price;Craig T. Jordan;Xiao Jin Yu.
Proceedings of the National Academy of Sciences of the United States of America (1999)
Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States
Antonia Kwan;Roshini S. Abraham;Robert Currier;Amy Brower.
Occurrence of leukaemia following gene therapy of X-linked SCID.
Donald B. Kohn;Michel Sadelain;Joseph C. Glorioso.
Nature Reviews Cancer (2003)
Immune response to green fluorescent protein: implications for gene therapy.
R. Stripecke;R. Stripecke;M. Del Carmen Villacres;D. C. Skelton;Noriko Satake.
Gene Therapy (1999)
T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates
Kohn Db;Hershfield Ms;Carbonaro D;Shigeoka A.
Nature Medicine (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: